Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jan;35(1):158–163. doi: 10.1128/aac.35.1.158

Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.

P D Walzer 1, C K Kim 1, J Foy 1, J L Zhang 1
PMCID: PMC244958  PMID: 2014971

Abstract

Furazolidone and nitrofurantoin, oral nitrofuran derivatives with broad-spectrum antimicrobial properties already in clinical use, were compared for activity against Pneumocystis carinii in an immunosuppressed rat model of P. carinii pneumonia. Furazolidone exhibited only slight activity as a prophylactic agent but was moderately effective in the therapy of pneumocystosis. The median histologic score and organism count fell from 4+ and 10(8) to 10(9) cysts per lung, respectively, in the controls to 1+ to 2+ and 10(7) to 10(8) cysts per lung, respectively, in the furazolidone-treated groups. However, these results were not as good as those obtained with the standard drug, trimethoprim-sulfamethoxazole (0+, 10(6) to 10(7) cysts per lung). Nitrofurantoin showed little anti-P. carinii activity despite different doses or drug preparations. The high doses of furazolidone used here and their toxic effects on the rats will probably discourage investigation of this drug in the treatment of pneumocystosis in humans. Nevertheless, since many nitrofurans have been synthesized, further exploration of this class of compounds might be helpful in developing new anti-P. carinii agents or in studying structure-activity relationships.

Full text

PDF
158

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali B. H., Hassan T., Malik K. H. The efficacy of furazolidone against experimental infections with Trypanosoma evansi in camels and mice in Sudan: comparisons with quinapyramine and suramin. Rev Elev Med Vet Pays Trop. 1986;39(2):197–201. [PubMed] [Google Scholar]
  2. Allegra C. J., Kovacs J. A., Drake J. C., Swan J. C., Chabner B. A., Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987 Mar 1;165(3):926–931. doi: 10.1084/jem.165.3.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berman J. D., Lee L. S. Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg. 1983 Sep;32(5):947–951. doi: 10.4269/ajtmh.1983.32.947. [DOI] [PubMed] [Google Scholar]
  4. Chamberlain R. E. Chemotherapeutic properties of prominent nitrofurans. J Antimicrob Chemother. 1976 Dec;2(4):325–336. doi: 10.1093/jac/2.4.325. [DOI] [PubMed] [Google Scholar]
  5. Costa J. M., Sampaio R. N., Tada M. S., Almeida E. A., Veiga E. P., Magalhães A. V., Marsden P. D. Furazolidone treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1985;79(2):274–274. doi: 10.1016/0035-9203(85)90358-x. [DOI] [PubMed] [Google Scholar]
  6. Crouch A. A., Seow W. K., Thong Y. H. Effect of twenty-three chemotherapeutic agents on the adherence and growth of Giardia lamblia in vitro. Trans R Soc Trop Med Hyg. 1986;80(6):893–896. doi: 10.1016/0035-9203(86)90249-x. [DOI] [PubMed] [Google Scholar]
  7. Cushion M. T., Ruffolo J. J., Linke M. J., Walzer P. D. Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Exp Parasitol. 1985 Aug;60(1):43–54. doi: 10.1016/s0014-4894(85)80021-7. [DOI] [PubMed] [Google Scholar]
  8. Cushion M. T., Stanforth D., Linke M. J., Walzer P. D. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob Agents Chemother. 1985 Dec;28(6):796–801. doi: 10.1128/aac.28.6.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DuPont H. L., Ericsson C. D., Galindo E., Wood L. V., Morgan D., Bitsura J. A., Mendiola J. G. Furazolidone versus ampicillin in the treatment of traveler's diarrhea. Antimicrob Agents Chemother. 1984 Aug;26(2):160–163. doi: 10.1128/aac.26.2.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  11. Hughes W. T., Feldman S., Chaudhary S. C., Ossi M. J., Cox F., Sanyal S. K. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978 Feb;92(2):285–291. doi: 10.1016/s0022-3476(78)80028-6. [DOI] [PubMed] [Google Scholar]
  12. Hughes W. T., McNabb P. C., Makres T. D., Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974 Mar;5(3):289–293. doi: 10.1128/aac.5.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kale O. O. Failure of furazolidone in the treatment of onchocerciasis. Tropenmed Parasitol. 1981 Mar;32(1):29–30. [PubMed] [Google Scholar]
  15. Kim C. K., Foy J. M., Cushion M. T., Stanforth D., Linke M. J., Hendrix H. L., Walzer P. D. Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987 Feb;31(2):197–201. doi: 10.1128/aac.31.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lerman S. J., Walker R. A. Treatment of giardiasis: literature review and recommendations. Clin Pediatr (Phila) 1982 Jul;21(7):409–414. doi: 10.1177/000992288202100704. [DOI] [PubMed] [Google Scholar]
  17. Lämmler G., Sänger I., Wegerhof P. H. Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis. 7. Filaricidal activity of furazolidone. Tropenmed Parasitol. 1978 Jun;29(2):178–182. [PubMed] [Google Scholar]
  18. McCann P. P., Bacchi C. J., Clarkson A. B., Jr, Bey P., Sjoerdsma A., Schecter P. J., Walzer P. D., Barlow J. L. Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. Am J Trop Med Hyg. 1986 Nov;35(6):1153–1156. doi: 10.4269/ajtmh.1986.35.1153. [DOI] [PubMed] [Google Scholar]
  19. Misra S., Chatterjee R. K., Sen A. B. Antifilarial action of furazolidone. Indian J Med Res. 1981 May;73:725–728. [PubMed] [Google Scholar]
  20. Murphy T. V., Nelson J. D. Five v ten days' therapy with furazolidone for giardiasis. Am J Dis Child. 1983 Mar;137(3):267–270. doi: 10.1001/archpedi.1983.02140290053014. [DOI] [PubMed] [Google Scholar]
  21. Ono T., Inoki S. Studies on the effects of furazolidon and P-rosaniline on the kinetoplast of Trypanosoma gambiense in mice. Biken J. 1976 Jun;19(2):63–69. [PubMed] [Google Scholar]
  22. Phillips K. F., Hailey F. J. The use of furoxone: a perspective. J Int Med Res. 1986;14(1):19–29. [PubMed] [Google Scholar]
  23. Queener S. F., Bartlett M. S., Richardson J. D., Durkin M. M., Jay M. A., Smith J. W. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1988 Jun;32(6):807–813. doi: 10.1128/aac.32.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rao P. K., Venkatanarayana M., Narasimham M. V., Rao C. K. Effect of furazolidone on Wuchereria bancrofti infection. J Commun Dis. 1983 Jun;15(2):129–130. [PubMed] [Google Scholar]
  25. Smith J. W., Bartlett M. S., Queener S. F., Durkin M. M., Jay M. A., Hull M. T., Klein R. S., Marr J. J. Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats. Diagn Microbiol Infect Dis. 1987 Jun;7(2):113–118. doi: 10.1016/0732-8893(87)90028-9. [DOI] [PubMed] [Google Scholar]
  26. St Omer V. V. Efficacy and toxicity of furazolidone in veterinary medicine. (A review). Vet Med Small Anim Clin. 1978 Sep;73(9):1125-8, 1132. [PubMed] [Google Scholar]
  27. Streeter A. J., Krueger T. R., Hoener B. A. Oxidative metabolites of 5-nitrofurans. Pharmacology. 1988;36(4):283–288. doi: 10.1159/000138396. [DOI] [PubMed] [Google Scholar]
  28. Tatsumi K., Nakabeppu H., Takahashi Y., Kitamura S. Metabolism in vivo of furazolidone: evidence for formation of an open-chain carboxylic acid and alpha-ketoglutaric acid from the nitrofuran in rats. Arch Biochem Biophys. 1984 Oct;234(1):112–116. doi: 10.1016/0003-9861(84)90330-8. [DOI] [PubMed] [Google Scholar]
  29. Vinayak V. K., Dhar U., Sethi R. K. In vitro antimicrobial effects of furazolidone & metronidazole. Indian J Med Res. 1986 Jul;84:39–43. [PubMed] [Google Scholar]
  30. Walzer P. D., Kim C. K., Foy J. M., Linke M. J., Cushion M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96–103. doi: 10.1128/aac.32.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walzer P. D., Kim C. K., Foy J., Linke M. J., Cushion M. T. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jun;32(6):896–905. doi: 10.1128/aac.32.6.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walzer P. D., Powell R. D., Jr, Yoneda K., Rutledge M. E., Milder J. E. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun. 1980 Mar;27(3):928–937. doi: 10.1128/iai.27.3.928-937.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wegerhof P. H., Lämmler G., Sänger I., Zahner H. Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis. 8. The action of furazolidone on adult worms and microfilariae. Tropenmed Parasitol. 1979 Sep;30(3):376–382. [PubMed] [Google Scholar]
  34. White A. H. Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature. Scand J Gastroenterol Suppl. 1989;169:4–10. doi: 10.3109/00365528909091325. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES